Company
Headquarters: Karlshamn, Sweden
Employees: 63
CEO: Mr. Richard Paxman
kr1.01 Billion
SEK as of July 1, 2024
US$95.3 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. It serves various cancer centers and hospitals. Paxman AB (Publ) has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. The company was founded in 1996 and is based in Karlshamn, Sweden.
Paxman AB has the following listings and related stock indices.
Stock: OMX: PAX wb_incandescent